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Background: Although the efficacy of zoledronic acid in postmenopausal women with breast cancer has been
suggested, the underlying mechanism has not been fully clarified. Therefore, which patients may benefit from
zoledronic acid and the optimal frequency of zoledronic acid administration are unclear. This study evaluates the
effects of zoledronic acid on the tumor response in postmenopausal women with breast cancer and explores the
relationship between its efficacy and γδ T cells.
Methods/design: This study is an open-label, multi-institutional, single-arm, phase II clinical trial. Zoledronic acid
will be administered once during preoperative hormonal therapy with letrozole for 24 weeks in postmenopausal
women with Estrogen Receptor (ER)-positive , Human Epidermal Growth Factor Receptor 2 (HER2)-negative, clinical
T1 or T2 N0M0 breast cancer. The primary endpoint is the objective response rate measured by MRI at 12 and
24 weeks. The secondary endpoints are the associations between the frequency of Vγ2Vδ2 T cells before the
administration of zoledronic acid and the objective response, the association between the frequency of Vγ2Vδ2 T
cells and the Preoperative Endocrine Prognostic Index score, and the association between the frequency of Vγ2Vδ2
T cells and Ki67 (MIB-1 index).
Discussion: This study is designed to determine the add-on effect of zoledronic acid during preoperative hormonal
therapy and to investigate the changes of the frequency of Vγ2Vδ2 T cells after the administration of zoledronic
acid to explore the potential mechanism of zoledronic acid in breast cancer patients.
Trial registration: This trial was registered at the UMIN Clinical Trials Registry as UMIN000008701.
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According to the 2008 National Breast Cancer Registry
Report [1], more than half of breast cancers are Estrogen
Receptor (ER)-positive, Human Epidermal Growth Factor
Receptor 2 (HER2)-negative, less than 5 cm in diameter
and negative for lymph node metastasis. Nevertheless,
treatment with paclitaxel and anthracycline-based com-
binations as an adjuvant therapy in ER-positive, HER2-
negative patients is less effective [2].
Hormonal therapy for early breast cancer has been
shown to be effective [3]. Anastrozole is as effective as
tamoxifen as a neoadjuvant treatment in postmeno-
pausal women [4,5]. Letrozole is also more effective
than tamoxifen as a preoperative treatment in postmen-
opausal patients with ER- and/or Progesterone Receptor
(PgR)-positive primary breast cancer, although the re-
sponse rate of 55% [6] is suboptimal.
Recently, the addition of zoledronic acid to adjuvant
endocrine therapy in premenopausal women with breast
cancer receiving goserelin improved disease-free survival
and reduced the risk of disease-free survival events over-
all [7]. Moreover, the rates of both disease-free survival
and overall survival were improved by the addition of
zoledronic acid in postmenopausal patients [8,9].
Zoledronic acid appears to be efficacious in patients
with early breast cancer [7-9] and in those with low levels
of estrogen or a deficiency of estrogen [7-9] after meno-
pause or oophorectomy and who were receiving hormonal
therapy [7,8].
The mechanism of the efficacy of zoledronic acid seems
to be through direct anti-tumor effects [10]. Many theo-
ries and hypotheses have been presented on the mecha-
nisms of zoledronic acid on tumor response [11-13]. The
involvement of immune cells, such as Vγ2Vδ2 T cell (also
called γδ T cells), has also been suggested [14]. Zoledronic
acid is one of the nitrogen-containing bisphosphonates
(N-BPs). N-BPs, such as zoledronic acid and pamidro-
nate, inhibit farnesyl diphosphate synthase, and its up-
stream metabolite diphosphomonoesters (e.g., isopentenyl
diphosphate) accumulate in tumor cells. Then, Vγ2Vδ2 T
cells specifically recognize and lyse the sensitized target
tumor cells that bear or express antigenic substances
[15,16]. The activated Vγ2Vδ2 T cells also secrete cyto-
kines, such as interferon-γ (IFN-γ) [17]. Although it was
demonstrated that the frequency of γδ T cells in periph-
eral blood was increased and that an acute-phase reaction
occurred after treatment with pamidronate [18], the causal
relationship between the function of γδ T cells and the ef-
ficacy of pamidronate has not been elucidated.
The hypothesis in this study is that zoledronic acid will
elicit an anti-tumor effect in patients with early breast
cancer who have a high frequency of γδ T cells in the
peripheral blood. In addition, the therapeutic roles of γδ T
cells might be determined by measuring body temperatureand IFN-γ production because γδ T cells secrete inflam-
matory cytokines in response to antigenic stimulation
through their T cell receptors. The aim of this study is to
examine the mechanism underlying the add-on effect of
zoledronic acid and to determine whether the initial fre-
quency of γδ T cells is related to the objective response
rate of patients with early breast cancer who receive hor-
mone therapy with zoledronic acid.
Objectives
The main objective of this study is to examine the add-
on effect of zoledronic acid in the treatment of postmen-
opausal women with ER-positive, HER2-negative breast
cancer who receive preoperative hormonal therapy by
letrozole. Other objectives are as follows: the determin-
ation of the frequency of Vγ2Vδ2 T cells in peripheral
blood before the administration of zoledronic acid, the
analysis of the associations between the frequency of
Vγ2Vδ2 T cells before the administration of zoledronic
acid, the objective response, the association between the
frequency and Preoperative Endocrine Prognostic Index




This study is an open-label, multi-institutional, single-
arm, phase II clinical trial. A total of 75 women will be
enrolled after they give written informed consent. The
study was approved by the ethical committee at Kyoto
University on October 18, 2012 (C-646) and will be ap-
proved by the ethical committees at the participating
hospitals prior to study initiation at each site. The study
protocol complies with the Helsinki declaration [19]
and the Ethics Guidelines for Clinical Research of the
Ministry of Health, Labor, and Welfare [20]. This study
was registered with the UMIN Clinical Trials Registry as
UMIN000008701 (http://www.umin.ac.jp/ctr/index.htm).
An additional study to investigate tumor infiltration with
γδ T cells at baseline, 12 weeks and 24 weeks was also ap-
proved by the ethical committee at Kyoto University on
June 1, 2013 (E1723).
Eligibility criteria
Women will be included in the study if they meet the
following criteria: have primary cT1-2, N0M0 breast
cancer; histologically confirmed invasive ductal cancer;
ER-positive and HER2-negative (i.e., as determined by
either immunohistochemistry (IHC) or by FISH/DISH
(fluorescence in situ hybridization/Dual Color in situ
Hybridization)) breast cancer; low levels or a deficiency
of estrogen (i.e., women aged 60 years or older that have
been postmenopausal for more than 4 years or have had
a post-bilateral oophorectomy); no prior treatment for
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within 6 weeks prior to study entry; an Eastern Coope-
rative Oncology Group (ECOG) performance score of 0
or 1; are within the age range of 20 to 75; have adequate
renal function with a Ccr (Cockcroft-Gault) > = 30 mL/
min; and have adequate hepatic function with serum
bilirubin < = 2.0 and AST/ALT < = 100.
Women will be excluded if they have: hyperparathyr-
oidism that requires management; uncontrolled diabetes
mellitus; diseases that require continuous management
with systemic corticosteroids; dental and/or periodontal
disease that requires invasive treatment after enrollment;
currently active or past malignancies within the past five
years; prior bisphosphonate therapy, if they have under-
gone hormone replacement therapy within 7 days prior
to enrollment; are hypersensitive to contrast materials
for MRI; or used other investigational drugs within 28
days prior to enrollment.
Intervention
Participants will take 2.5 mg/day of letrozole orally
within 7 days of enrollment in the study. Participants will
receive a single-drip injection of zoledronic acid on day
28. The dose of zoledronic acid will be reduced when the
participants demonstrate impaired renal function (i.e.,
when the Ccr is equal to or less than 60 mL/min) accord-
ing to Table 1. A single administration of zoledronic acid
is expected to be effective because frequent zoledronic
acid treatments lead to a decrease in blood Vγ2Vδ2 T cell
levels [14]. Cytokines such as IL-2 are not used in combin-
ation with zoledronic acid because patients with early
breast cancer without any previous treatment have a po-
tential to restore immune responses against tumor anti-
gens without administration of cytokines such as IL-2.
Participants will take letrozole every day for 24 to 26 weeks
until they have a mastectomy as a part of routine medical
care. The study treatment will be terminated upon disease
progression, episodes of serious adverse events, or in pa-
tients for whom zoledronic acid cannot be administered
within 35 days of starting letrozole treatment.
Measurements
Patients will be evaluated clinically and through labora-
tory testing, radiological testing and pathological testing,
according to Table 2.
The primary endpoint is the objective response rate
(ORR). The ORR is defined as the proportion of the com-
plete response (CR) and the partial response (PR) withinTable 1 Dose of zoledronic acid
Ccr (mL/min)
>60 50 - 60 40 - 49 30 - 39
Dose of zoledronic acid 4 mg 3.5 mg 3.3 mg 3.0 mgthe best overall response based on MRI evaluation. Pa-
tients will undergo tumor assessments at baseline, 12
weeks and 24 weeks by investigators using the Response
Evaluation Criteria in Solid Tumors (RECIST) version 1.1
[21]. The imaging modality is restricted to MRI because
MRI is superior to other modalities for the detection and
staging of invasive breast cancer, and MRI measurements
after neoadjuvant treatment are more highly correlated
with pathological tumor size than mammography or ultra-
sound [22]. The secondary endpoints are the change in
tumor volume, ORRs using ultrasonography or clinical as-
sessment, breast-conserving surgery, the frequency of
Vγ2Vδ2 T cells, PEPI score [23], Ki67 (MIB-1 index) and
safety.
Tumor volume will be measured using MRI volumetry
at baseline, 12 weeks and 24 weeks by an independent
committee. The contrast-enhanced MRI will be performed
according to the European Society of Breast Imaging
(EUSOBI) guidelines [24]. ORRs using ultrasonography or
clinical assessment will be evaluated separately by the in-
vestigators according to RECIST. A partial resection of
the breast will be regarded as breast-conserving surgery
after the completion of letrozole treatment.
The frequency of Vδ1+ T cells and Vδ2+ T cells among
CD3+ T cells in peripheral blood mononuclear cells will
be analyzed by two-color flow cytometry [11] and will be
evaluated at baseline, 4 weeks and 20 weeks after the ad-
ministration of zoledronic acid.
Peripheral mononuclear cells (PBMC) will be purified by
density gradient centrifugation. For flow cytometric ex-
periments, 2 × 105 cells of PBMC in each well will be
stained with mAbs. The following mAbs will be used: fluo-
rescein isothiocyanate (FITC)-conjugated anti- Vδ1 mAbs
(Thermo Scientific, Rockford, IL), Vδ2 mAbs (Beckman
Coulter Inc., Fullerton, CA), anti-CD3 mAbs (BioLegend,
San Diego, CA), phycoerythrin (PE)-conjugated anti-CD3,
CD4, CD8, CD25, NKG2D mAbs (BD Biosciences, San
Diego, CA) and FcR blocking reagent (Miltenyi Biotec
GmbH, Bergisch Gradbach, Germany) will be used. The
stained cells will be subjected to 2-color flow cytometry
using a FACSCalibur flow cytometer (Becton–Dickinson,
Franklin Lakes, NJ) and the analyses will be performed
on a single sample. The serum at 5 hours after administra-
tion of zoledronic acid will be collected and subjected to
ELISA for IFN-γ level using an ELISA Kit (PEPROTECH,
Rocky Hill, NJ) according to the manufacturer’s instruc-
tions. The analyses will be conducted on triplicate samples.
Adverse events will be evaluated according to the
Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0 [25].
Data analysis
The sample size was determined using the Bayesian me-
thod based on predictive distributions [26,27]. The ORR
Table 2 Trial schedule
Protocol treatments and assessments Pre-enrollment Week 1 Week 4 Week8 Week 12 Week 16 Week 20 Week 24 Mastectomy
Protocol treatments Letrozole
Zoledronic acid ↓
Demographics, current medications, dental examination ○
Physical examination ○ ○1
Complete blood count, blood biochemical test, bone metabolism markers ○ ○2 ○ ○ ○
Enhanced MRI, tumor markers ○ ○ ○
Palpation, ultrasound examination ○ ○ ○ ○ ○ ○ ○
Vδ1+ T cells and Vδ2+ T cells in peripheral blood 3 ○ ○ ○
IFN- γ 4 ○
Pathological examination5 ○ ○ ○
PEPI score ○
1Body temperature before and 4–6 hours after the administration of zoledronic acid.
2Bone metabolism markers that are expected.
3The frequency of Vδ1+ T cells and Vδ2+ T cells among CD3+ T cells in peripheral blood.
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to be 45% [28]. The threshold ORR of 45% was used as
the prespecified target value for the primary endpoint.
The uniform distribution and the degenerated distribution
at an expected ORR of 60% were used as the analysis prior
and the design prior, respectively. The sample size of 75 is
required to preserve the Bayesian power of 80% with a
prespecified probability threshold of 95% to declare the
treatment efficacious.
The primary statistical analysis will be performed using
the Bayesian approach according to the intention-to-treat
principle. The posterior beta distribution of the ORR will
be calculated using the prior uniform distribution. If the
posterior probability that the ORR is greater than the pre-
specified target value of 45% exceeds a prespecified prob-
ability threshold of 95%, the treatment will be considered
efficacious.
A subset analyses for the ORR based on MRI and tu-
mor volume using MRI volumetry according to (a) equal
and greater or less than the median of the frequency of
Vγ2Vδ2 T cells before the administration of zoledronic
acid, (b) equal and greater or less than the median of
IFN-γ at 5 hours after the administration of zoledronic
acid and (c) presence of fever and/or flu-like symptoms,
are planned. Exploratory subgroup analyses for the fre-
quency of Vγ2Vδ2 T cells according to (a) equal and
greater or less than a body mass index of 25, (b) 0, 1–3,
or over 3 of PEPI score, (c) equal and greater or less
than 14 of Ki67, (d) equal and greater or less than the
median of IFN-γ at 5 hours after the administration of
zoledronic acid and (e) presence of fever and/or flu-like
symptoms, are also planned.
Discussion
We presented the design of a single-arm phase II study
to evaluate the add-on effect of zoledronic acid in pre-
operative hormonal therapy. The single-arm design will
not clarify whether the frequency of Vγ2 T cells before
administration of zoledronic acid influences the out-
come of breast cancer patients regardless of zoledronic
acid or if they influence the outcome related to admin-
istration of zoledronic acid. Nevertheless, the changes
of the frequency of Vγ2Vδ2 T cells after the administra-
tion of zoledronic acid suggest the potential immuno-





ER: Estrogen receptor; HER2: Human epidermal growth factor receptor 2;
N-BPs: Nitrogen-containing bisphosphonates; IFN-γ: Interferon-γ;
PEPI: Preoperative endocrine prognostic index; IHC: immunohistochemistry;
FISH: Fluorescence in situ hybridization; DISH: Dual color in situ Hybridization;ECOG: Eastern cooperative oncology group; ORR: Objective response rate;
CR: Complete response; PR: Partial response; RECIST: Response evaluation
criteria in solid tumors; EUSOBI: European society of breast imaging;
CTCAE: Common terminology criteria for adverse events.
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